TMO

Thermo Fisher Scientific
D

TMO

Arincen67/100B

Thermo Fisher Scientific income statement 1985–2026

47.35B USD over the last twelve months, and 44.56B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
26 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
47.35B44.56B42.88B42.86B44.92B39.21B32.22B25.54B24.36B20.92B18.27B
Revenue growth
+8.27%+3.91%+0.05%-4.58%+14.55%+21.71%+26.14%+4.86%+16.45%+14.47%+7.71%
Cost of revenue
27.73B26.32B25.15B25.66B25.90B19.58B16.19B14.20B13.37B11.24B9.69B
Gross profit
19.62B18.24B17.73B17.19B19.01B19.63B16.03B11.34B10.99B9.68B8.58B
Gross margin
41.44%40.93%41.34%40.12%42.33%50.07%49.75%44.41%45.11%46.27%46.96%
Research and development
1.41B1.40B1.39B1.34B1.47B1.41B1.18B1.00B967.00M888.00M754.80M
Selling, general and administrative
7.92B8.73B8.68B8.41B9.02B7.91B6.95B6.06B6.03B5.41B4.87B
Operating expenses
11.11B10.13B10.07B9.75B10.49B9.32B8.13B7.09B7.12B6.41B5.72B
8.52B8.11B7.66B7.45B8.53B10.32B7.90B4.26B3.87B3.27B2.86B
Operating income growth
+5.12%+5.83%+2.90%-12.66%-17.38%+30.66%+85.42%+9.99%+18.52%+14.27%+14.61%
Operating margin
17.98%18.20%17.87%17.37%18.98%26.31%24.51%16.67%15.90%15.62%15.64%
Interest income
950.00M993.00M1.08B879.00M272.00M43.00M65.00M224.00M137.00M81.00M48.40M
Interest expense
1.54B1.42B1.65B1.49B726.00M536.00M553.00M676.00M667.00M592.00M469.60M
Other non-operating income
-646.00M-842.00M-667.00M-1.21B-862.00M-1.48B-670.00M-189.00M-610.00M-838.00M-835.00M
Pretax income
7.87B7.27B7.00B6.24B7.66B8.84B7.23B4.07B3.26B2.43B2.02B
Income tax
742.00M547.00M657.00M284.00M703.00M1.11B850.00M374.00M324.00M201.00M-1.40M
Effective tax rate
9.43%7.53%9.39%4.55%9.17%12.55%11.76%9.19%9.93%8.28%-0.07%
7.08B6.74B6.34B6.00B6.95B7.73B6.38B3.70B2.94B2.23B2.02B
Net income growth
+7.81%+6.35%+5.67%-13.74%-10.03%+21.18%+72.48%+25.80%+32.04%+10.05%+2.35%
Net margin
14.96%15.12%14.77%13.99%15.47%19.70%19.79%14.47%12.06%10.64%11.06%
Basic shares
372.25M376.00M382.00M386.00M392.00M394.00M396.00M400.00M402.00M395.00M394.80M
373.00M377.00M383.00M388.00M394.00M397.00M399.00M403.00M406.00M398.00M397.40M
Change in diluted shares
-1.71%-1.57%-1.29%-1.52%-0.76%-0.50%-0.99%-0.74%+2.01%+0.15%-1.12%
EPS (basic)
18.9917.7716.5815.5317.7319.6116.109.247.315.645.12
18.9617.7416.5315.4517.6419.4615.989.177.245.595.09
EPS growth
+9.53%+7.32%+6.99%-12.42%-9.35%+21.78%+74.26%+26.66%+29.52%+9.82%+3.46%
Dividends per share
1.841.721.561.401.201.040.880.760.680.600.60
Dividend growth
+9.52%+10.26%+11.43%+16.67%+15.38%+18.18%+15.79%+11.76%+13.33%0.00%0.00%
EBITDA
11.24B11.47B11.80B11.20B11.94B11.97B10.11B7.02B6.20B5.05B4.25B
EBITDA margin
23.74%25.73%27.52%26.12%26.59%30.52%31.37%27.50%25.44%24.16%23.27%
EBIT
8.96B8.69B8.69B7.79B8.56B9.38B7.78B4.75B3.93B3.02B2.49B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Thermo Fisher Scientific's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.